DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Hepsera (Adefovir Dipivoxil) - Published Studies

 
 



Hepsera Related Published Studies

Well-designed clinical trials related to Hepsera (Adefovir Dipivoxil)

[One-year combination therapy de novo of adefovir dipivoxil and lamivudine for decompensated cirrhosis related to HBV]. [2011.04]

Peginterferon plus adefovir versus either drug alone for hepatitis delta. [2011.01.27]

Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study. [2010.01]

[Efficacy and durability of generic adefovir dipivoxil in patients with HBeAg positive chronic hepatitis] [2009.12]

[The analyse of effectiveness in HBeAg-positive chronic viral hepatitis B treated by adefovir dipivoxil combined with bicyclol] [2009.08]

HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapy. [2009.05]

Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. [2009.03]

Complex dynamics of hepatitis B virus resistance to adefovir. [2009.01]

A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. [2009]

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. [2008.12.04]

A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. [2008.11]

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. [2008.09]

The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection. [2008.04]

Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. [2008]

Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. [2007.12.04]

Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B. [2007.12]

Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. [2007.11.15]

Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis with Telbivudine or Adefovir: A Randomized Trial. [2007.10.01]

[Efficacy of adefovir dipivoxil was not related to genotypes B and C of hepatitis B virus: A randomized, double-blind, multicenter clinical study.] [2007.09]

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. [2007.02]

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. [2006.12]

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. [2006.11]

[A double-blind, randomized, lamivudine-controlled clinical trial of DAIDING (adefovir dipivoxil) for lamivudine-resistant patients with chronic hepatitis B] [2006.11]

A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. [2006.07]

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. [2005.06.30]

Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. [2004.09]

Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy. [2004.01]

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. [2004.01]

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. [2004.01]

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. [2003.07]

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. [2003.07]

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. [2003.02.27]

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. [2003.02.27]

The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. [2001.09.07]

Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408. [2001.08.15]

Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. [1999.12.22]

A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. [1999.09]

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. [1998.07]

The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. [1997.12]

Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. [1997.08]

Well-designed clinical trials possibly related to Hepsera (Adefovir Dipivoxil)

Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents. [2011.04]

No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. [2011.03]

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. [2011.01]

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. [2011]

Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. [2005.10.07]

Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. [2003.01]

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. [2002.07.10]

Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884. [2000.11.10]

Other research related to Hepsera (Adefovir Dipivoxil)

Comparison of the antiviral effects of entecavir and adefovir dipivoxil in chronic HBV infection: a randomized control trial. [2012]

Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B. [2012]

[The therapeutic effect of Anluohuaxian capsule combined with adefovir dipivoxil on patients with chronic hepatitis B and influence on hepatic histology]. [Article in Chinese] [2012]

Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. [2012]

Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection. [2012]

Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B. [2012]

A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol. [2011.07.20]

[Relationship between HBeAg seroconversion with genotypes and HBV specific CTL in patients with chronic hepatitis B treated with Adefovir dipivoxil]. [2011.06]

Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. [2011.06]

[The levels of HBsAg can predict the efficacy of peglated interferon-alpha 2a combined with adefovir dipivoxil, in HBeAg-positive chronic hepatitis B patients]. [2011.04]

Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B. [2011.04]

[Virological response to adefovir dipivoxil predicts the long-term development of resistance in previously untreated patients with HBeAg-negative chronic hepatitis B]. [2011.02]

Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience. [2011.02]

Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. [2011.02]

Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies. [2011.01]

[The clinical efficacy and safety of adefovir dipivoxil in combination with bicyclol for the treatment of senior patients with chronic hepatitis B]. [Article in Chinese] [2011]

[One-year combination therapy de novo of adefovir dipivoxil and lamivudine for decompensated cirrhosis related to HBV]. [Article in Chinese] [2011]

Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. [2010.10]

[Influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B]. [2010.10]

[The efficacy of adefovir dipivoxil, entecavir and telbivudine for chronic hepatitis B treatment: a systematic review] [2010.08]

Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation. [2010.07.07]

[Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B]. [2010.06]

Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. [2010.04]

Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. [2010.02.01]

[Short-term efficacy of adefovir dipivoxil as an add-on therapy in the pegylated IFNalpha-2a treatment for HBeAg positive chronic hepatitis B patients] [2010.02]

Overlap/switch to adefovir monotherapy for lamivudine-resistant patients who responded to combination therapy: a pilot controlled study. [2010]

Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. [2010]

Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. [2010]

Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. [2010]

[Short-term efficacy of adefovir dipivoxil as an add-on therapy in the pegylated IFNalpha-2a treatment for HBeAg positive chronic hepatitis B patients]. [Article in Chinese] [2010]

Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation. [2010]

Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study. [2010]

Favorable outcome of de novo hepatitis B infection after liver transplantation with lamivudine and adefovir therapy. [2009.12]

Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. [2009.10.09]

Detection of the rtA181V/T and rtN236T mutations associated with resistance to adefovir dipivoxil using a ligase detection reaction assay. [2009.10]

Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg chronic hepatitis B patients: A 4-year study. [2009.09.22]

Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. [2009.09]

Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. [2009.07]

[A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period] [2009.07]

Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis. [2009.05]

Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy. [2009.04]

A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. [2009.04]

[Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients] [2009.03]

Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. [2009]

Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. [2009]

Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B. [2009]

Clinical usefulness of sequential hepatitis B virus DNA measurement (the roadmap concept) during adefovir treatment in lamivudine-resistant patients. [2009]

Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance. [2009]

Serum levels of surface large envelope proteins: prognostic markers for hepatitis B e antigen-negative patients with adefovir dipivoxil treatment. [2009]

Two types of drug-resistant hepatitis B viral strains emerging alternately and their susceptibility to combination therapy with entecavir and adefovir. [2009]

[The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection] [2008.12]

Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants. [2008.11.15]

Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. [2008.10.22]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012